Nimustine + Procarbazine

This entry pertains to the drug combination nimustine + procarbazine. However, the provided search results do not specifically mention this combination. Instead, they primarily discuss procarbazine individually and as part of the PCV combination (procarbazine, lomustine, and vincristine) for brain tumors. Procarbazine is a chemotherapy medication used for treating Hodgkin's lymphoma and brain cancers. It is typically taken orally as capsules and works by destroying quickly dividing cells, such as cancer cells. When used for brain tumors, procarbazine is often combined with other drugs in regimens like PCV (procarbazine, lomustine, and vincristine). For brain cancer treatment, PCV is administered with vincristine given intravenously while lomustine and procarbazine are taken as capsules. This combination is used to shrink tumors, decrease symptoms of brain cancer, and slow disease progression, though it's not commonly given with the goal of cure. Procarbazine was approved for medical use in the United States in 1969 and is on the World Health Organization's List of Essential Medicines. It's classified as an alkylating agent, though its exact mechanism of action is not clearly known. Common side effects of procarbazine include low blood cell counts, vomiting, tiredness, and depression. It's not recommended for people with severe liver or kidney problems, and use during pregnancy is known to harm the baby. Nimustine is described as similar to lomustine, but they are different drugs.